Early antithrombotic post-discharge therapy using prophylactic DOAC or dipyridamole improves long-term survival and cardiovascular outcomes in hospitalized COVID-19 survivors
IntroductionCardiovascular events are common in COVID-19. While the use of anticoagulation during hospitalization has been established in current guidelines, recommendations regarding antithrombotic therapy in the post-discharge period are conflicting.MethodsTo investigate this issue, we conducted a...
Main Authors: | Lukas J. Motloch, Peter Jirak, Moritz Mirna, Lukas Fiedler, Paruir A. Davtyan, Irina A. Lakman, Diana F. Gareeva, Anton V. Tyurin, Ruslan M. Gumerov, Simon T. Matskeplishvili, Valentin N. Pavlov, Benzhi Cai, Kristen Kopp, Albert Topf, Uta C. Hoppe, Rudin Pistulli, Naufal S. Zagidullin |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-07-01
|
Series: | Frontiers in Cardiovascular Medicine |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2022.916156/full |
Similar Items
-
Cardiovascular Biomarkers for Prediction of in-hospital and 1-Year Post-discharge Mortality in Patients With COVID-19 Pneumonia
by: Lukas J. Motloch, et al.
Published: (2022-06-01) -
Prophylactic rivaroxaban in the early post-discharge period reduces the rates of hospitalization for atrial fibrillation and incidence of sudden cardiac death during long-term follow-up in hospitalized COVID-19 survivors
by: Lukas Fiedler, et al.
Published: (2023-05-01) -
Investigation of hs-TnI and sST-2 as Potential Predictors of Long-Term Cardiovascular Risk in Patients with Survived Hospitalization for COVID-19 Pneumonia
by: Lukas Fiedler, et al.
Published: (2022-11-01) -
Long-Term Outcomes of COVID-19 in Hospitalized Type 2 Diabetes Mellitus Patients
by: Zemfira Khamidullina, et al.
Published: (2024-02-01) -
Potential therapeutic effects of dipyridamole in the severely ill patients with COVID-19
by: Xiaoyan Liu, et al.
Published: (2020-07-01)